A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol

A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol

Patients with symptomatic advanced chronic obstructive pulmonary disease (COPD) who experience recurrent exacerbations are particularly at risk of poor outcomes and present a significant burden on healthcare systems. The relative merits of treating with different inhaled combination therapies e.g. i...

Full description

Bibliographic Details
Main Authors:	Pascoe, S, Lipson, D, Locantore, N, Barnacle, H, Brealey, N, Mohindra, R, Dransfield, M, Pavord, I, Barnes, N
Format:	Journal article
Language:	English
Published:	European Respiratory Society 2016

Similar Items

The association between blood eosinophils and risk and treatment outcome in COPD is not dichotomised
by: Pascoe, S, et al.
Published: (2018)

Blood eosinophil levels as a biomarker in COPD
by: Brusselle, G, et al.
Published: (2018)

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids
by: Siddiqui, S, et al.
Published: (2018)

The significance of eosinophilic inflammation in COPD
by: Cooper, C, et al.
Published: (2017)

Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.
by: Siva, R, et al.
Published: (2007)

SINFONIA study protocol: a phase II/III randomised controlled trial examining benefits of guided online group singing in people with chronic obstructive pulmonary disease and interstitial lung disease and their carers
by: Natasha Smallwood, et al.
Published: (2022-08-01)

Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial
by: Lee, LA, et al.
Published: (2020)

Whole-body hypothermia in mild neonatal encephalopathy: protocol for a multicentre phase III randomised controlled trial
by: Garegrat, R, et al.
Published: (2024)

The Lancet COPD Commission: broader questions remain
by: Petousi, N, et al.
Published: (2023)

Symptomatic COPD: is it time for triple therapy?
by: Bafadhel, M
Published: (2018)

Triple therapy in COPD: understanding the data
by: Samy Suissa
Published: (2023-01-01)

Impact of triple therapy on mortality in COPD
by: Thibaud Soumagne, et al.
Published: (2023-03-01)

CryptoDex: a randomised, double-blind, placebo-controlled phase III trial of adjunctive dexamethasone in HIV-infected adults with cryptococcal meningitis: study protocol for a randomised control trial.
by: Day, N, et al.
Published: (2014)

High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial
by: Sonja Vliek, et al.
Published: (2023-09-01)

A Delphi Consensus Document on the Use of Single-Inhaler Fixed-Dose Triple Therapies in COPD Patients
by: López-Campos JL, et al.
Published: (2020-07-01)

Effectiveness of manual therapy in COPD: A systematic review of randomised controlled trials
by: C. Simonelli, et al.
Published: (2019-07-01)

Assessing the impact of diverse mask types on COPD patients: a randomised controlled trial study protocol
by: Hong Yang, et al.
Published: (2024-01-01)

COPD and hepatitis C.
by: Pavord, I, et al.
Published: (2003)

COPD: an autoimmune disease?
by: Birring, S, et al.
Published: (2011)

Efficacy of different respiratory supports to prevent hypoxia during flexible bronchoscopy in patients of COPD: a triple-arm, randomised controlled trial
by: Pawan Kumar Singh, et al.
Published: (2023-12-01)

Inhaled corticosteroids in COPD.
by: Brightling, C, et al.
Published: (1999)

Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
by: Pavord, I, et al.
Published: (2017)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
by: Nicola C. Day, et al.
Published: (2020-06-01)

Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS Score
by: Paola Rogliani, et al.
Published: (2022-08-01)

Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution
by: Fulvio Braido, et al.
Published: (2022-01-01)

Participate CP 2: optimising participation in physically active leisure for children with cerebral palsy – protocol for a phase III randomised controlled trial
by: Robert S Ware, et al.
Published: (2023-10-01)

Study protocol for a phase III randomised controlled trial of Sailuotong (SLT) for vascular dementia and Alzheimer’s disease with cerebrovascular disease
by: Diana Karamacoska, et al.
Published: (2023-01-01)

Study protocol for a phase III randomised controlled trial of Sailuotong (SLT) for vascular dementia and Alzheimer's disease with cerebrovascular disease.
by: Diana Karamacoska, et al.
Published: (2023-01-01)

Self management of patients with mild COPD in primary care: Randomised controlled trial
by: Jolly, K, et al.
Published: (2018)

Mepolizumab for eosinophilic COPD
by: Sciurba, F, et al.
Published: (2018)

Determinants of successful completion of pulmonary rehabilitation in COPD
by: Brown AT, et al.
Published: (2016-02-01)

Triple Therapy for COPD: Historical Perspective and Current Controversies
by: Jose L. López-Campos
Published: (2023-01-01)

Protocol for the air purification for eosinophilic COPD study (APECS): a randomised controlled trial of home air filtration by HEPA
by: Mary B Rice, et al.
Published: (2024-01-01)

Discordant diagnostic criteria for pneumonia in COPD trials: a review
by: Robert A. Wise, et al.
Published: (2021-11-01)

COPD exacerbation phenotypes: The next frontier
by: Moran, A, et al.
Published: (2019)

Inhaled glucocorticoids and COPD exacerbations.
by: Brightling, C, et al.
Published: (2015)

Prednisolone response in patients with COPD.
by: Pavord, I, et al.
Published: (2004)

A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial
by: Hanratty, CE, et al.
Published: (2018)

Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost–utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)
by: Carlos Suso-Ribera, et al.
Published: (2022-01-01)

Symptomatic burden of COPD for patients receiving dual or triple therapy
by: Chen S, et al.
Published: (2018-04-01)